Risks of using ursodeoxycholic acid to treat primary sclerosing cholangitis

Affiliations

Comment

Michael L Volk. Gastroenterology. 2011 Dec.

. 2011 Dec;141(6):2267-8.

doi: 10.1053/j.gastro.2011.10.003. Epub 2011 Oct 24.

¹ Division of Gastroenterology and Hepatology, University of Michigan Health System, Ann Arbor, Michigan, USA.

No abstract available

Comment on

High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.
Eaton JE, Silveira MG, Pardi DS, Sinakos E, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Lindor KD. Eaton JE, et al. Am J Gastroenterol. 2011 Sep;106(9):1638-45. doi: 10.1038/ajg.2011.156. Epub 2011 May 10. Am J Gastroenterol. 2011. PMID: 21556038 Free PMC article. Clinical Trial.